Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).

Rafal Dziadziuszko,Xiao Li,Eric C. Anderson,Alona Zer,Luis Corrales-Rodriguez,Parneet Cheema,Aleksandra Szczęsna,Manuel Philco,M. Mathisen,Sarah M. Paul,Vijay Bhagawati-Prasad,Gaurav Pathria,Zhen Shi,Magalie Hilton,Qing Zhang

Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).

2021

Rafal Dziadziuszko
Xiao Li
Eric C. Anderson
Alona Zer
Luis Corrales-Rodriguez
Parneet Cheema
Aleksandra Szczęsna
Manuel Philco
M. Mathisen
Sarah M. Paul
Vijay Bhagawati-Prasad
Gaurav Pathria
Zhen Shi
Magalie Hilton
Qing Zhang

9023Background: BFAST (NCT03178552) is a global, multicohort trial of targeted therapies or cancer immunotherapy (CIT) in treatment (tx)-naive aNSCLC. Pts are screened for the study using comprehen...

Keywords:

real world data
Screening Trial
Oncology
Lung cancer
non small cell
Medicine
Natural history
KRAS
Internal medicine
Cohort
Cancer immunotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations